Sygnature Discovery, the Nottingham-headquartered drug discovery company, has established a new office presence in South San Francisco.
The new office follows Sygnature’s recent expansion in Nottingham and the opening of a second co-located integrated drug discovery site on the research campus at Alderley Park, UK.
Sygnature established its first US office in 2019 in the heart of the Cambridge–Boston biotech hub in Massachusetts, and says the new expansion will help meet growing demand from US customers ranging from major pharma through to small seed-funded biotechs.
“Our very first client was actually from the US,” said Simon Hirst, Sygnature’s CEO and founder. “It remains a very significant market for us, both now and in our future strategy. It’s fantastic to have a base on the west coast, and in such a vibrant hub for the life sciences community.
“Our approach to drug discovery is based on true collaboration and partnership with our clients, and having a physical presence near to many of them helps us to work the way we believe in – strengthening those ties and relationships that lead to success.”
The new office is located on Gateway Boulevard, Oyster Point, in South San Francisco.